Compare LMB & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMB | COLL |
|---|---|---|
| Founded | 1901 | 2002 |
| Country | United States | United States |
| Employees | 1400 | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2014 | 2015 |
| Metric | LMB | COLL |
|---|---|---|
| Price | $78.10 | $33.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $116.67 | $51.40 |
| AVG Volume (30 Days) | 339.3K | ★ 377.5K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.68 | N/A |
| EPS | 0.36 | ★ 0.40 |
| Revenue | $646,804,000.00 | ★ $780,567,000.00 |
| Revenue This Year | $15.96 | $8.01 |
| Revenue Next Year | $5.90 | N/A |
| P/E Ratio | $225.81 | ★ $84.18 |
| Revenue Growth | ★ 24.68 | 23.62 |
| 52 Week Low | $65.08 | $28.74 |
| 52 Week High | $154.04 | $50.79 |
| Indicator | LMB | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 47.79 | 43.08 |
| Support Level | $76.97 | $31.56 |
| Resistance Level | $78.12 | $36.22 |
| Average True Range (ATR) | 4.46 | 1.46 |
| MACD | 0.26 | -0.15 |
| Stochastic Oscillator | 61.65 | 5.79 |
Limbach Holdings Inc is a building systems solutions firm that designs, delivers, and maintains mechanical (heating, ventilation, and air conditioning), electrical, plumbing, and controls (MEPC) systems. The Company partners with owners and operators of facilities across healthcare, industrial and manufacturing, data centers, life sciences, higher education, and cultural and entertainment markets. It operates through two segments: Owner Direct Relationships (ODR), which generates maximum revenue and includes owner direct projects, maintenance, and service on MEPC systems; and General Contractor Relationships (GCR), which manages new construction or renovation projects involving MEPC systems awarded by general contractors or construction managers.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.